Thus, the second-generation CDK9 selective inhibitor voruciclib was developed.24 Voruciclib has greater specificity for CDK9 than flavopiridol, downregulates Mcl-1, and synergizes with venetoclax in diffuse large B cell lymphoma in vitro and in vivo. Here, MCL1 is linked to diffuse large B-cell lymphoma.